Ian Read

Ian Read
Name	Ian Read
Birth date	1953
Birth place	Methil, Fife, Scotland
Nationality	British
Alma mater	University of Edinburgh, University of Washington
Occupation	Businessman, Executive
Known for	Former Chairman and CEO of Pfizer

Ian Read Ian Read is a Scottish-born business executive notable for his tenure as Chairman and Chief Executive Officer of Pfizer and for leadership roles within multinational corporations and trade associations. He managed global operations that spanned pharmaceutical research, manufacturing, and commercial strategy while engaging with regulators, investors, and international institutions. Read’s career intersects with major corporate governance developments, mergers and acquisitions, and public health policy debates.

Early life and education

Born in Methil, Fife, Scotland, Read attended local schools before pursuing higher education at the University of Edinburgh, where he studied chemical engineering. He later completed an MBA at the University of Washington Foster School of Business, preparing him for roles at multinational firms including Shell plc and Pfizer. His education linked him to professional networks such as alumni associations of the University of Edinburgh and business programs that foster connections to corporate boards like The Business Roundtable and industry groups including the Pharmaceutical Research and Manufacturers of America.

Career

Read began his professional career at Shell Oil Company in operations and commercial roles, gaining experience in energy markets and industrial management. He joined Pfizer in the 1990s, initially working in international finance and corporate strategy before assuming executive positions in Latin America and global commercial operations. Over decades at Pfizer, he held roles that brought him into contact with major pharma initiatives, cross-border transactions, and regulatory processes involving agencies such as the U.S. Food and Drug Administration, the European Medicines Agency, and national health services across Europe and Latin America.

During his ascent, Read worked alongside senior executives including Jeffrey Kindler and Henry McKinnell, and engaged with institutional investors like BlackRock, Vanguard Group, and State Street Corporation on governance and performance issues. His career encompassed participation in corporate actions and strategic reviews that intersected with events such as the rise of biotechnology firms like Amgen and Genentech, and consolidation trends exemplified by mergers involving Allergan and other major industry players.

Leadership at Pfizer

Appointed Chief Executive Officer of Pfizer in 2010 and later Chairman, Read led the company through a period marked by portfolio realignment, patent expirations, and product launches. He oversaw global brands and franchises, including blockbuster medicines whose patents were central to discussions in legal venues like the United States Supreme Court and health policy forums organized by the World Health Organization.

Under Read’s leadership, Pfizer pursued strategic transactions and alliances with firms such as Wyeth (whose integration remained a legacy issue), engaged in licensing deals with biotech companies including Medivation and Anacor Pharmaceuticals, and navigated challenges from generic manufacturers such as Teva Pharmaceutical Industries and Mylan. He directed responses to market pressures and shareholder activism from entities like Elliott Management Corporation and coordinated with regulatory authorities in antitrust matters involving the Federal Trade Commission and competition authorities in the European Union.

Business strategy and impact

Read emphasized cost discipline, operational efficiency, and a shift toward innovative pipelines, prioritizing research collaborations and acquisitions to offset patent cliffs that affected products like those previously marketed by Pfizer and competitors such as Merck & Co. and AstraZeneca. He advocated for strategic realignment, including divestitures and reinvestment in biologics and specialty care, echoing industry moves seen at Johnson & Johnson and Novartis.

His tenure influenced corporate governance practices, executive compensation debates, and investor relations strategies, drawing scrutiny from major proxy advisory firms like Institutional Shareholder Services and Glass Lewis as well as engagement with pension funds including the California Public Employees' Retirement System and sovereign wealth entities. Read’s stewardship affected global pharmaceutical supply chains, interactions with procurement agencies such as NHS England, and participation in public-private partnerships addressing neglected diseases in collaboration with organizations like the Bill & Melinda Gates Foundation.

Personal life and philanthropy

Read is known for maintaining a relatively private personal life while participating in philanthropic and civic activities. He has served on boards and advisory councils, linking to institutions such as the Wharton School events and industry forums hosted by the Brookings Institution and Council on Foreign Relations. His philanthropic interests have touched healthcare initiatives and education programs, aligning with philanthropic efforts by peers at companies like GlaxoSmithKline and foundations such as Wellcome Trust.

He has residences that reflected his international career footprint and has been recognized in lists of influential executives compiled by publications including Fortune (magazine), The Wall Street Journal, and Financial Times. Read’s leadership legacy remains a subject of analysis in business schools and corporate governance research at institutions such as Harvard Business School and INSEAD.

Category:1953 births Category:British chief executives Category:Pfizer people